Optimal duration of dual antiplatelet therapy following treatment with the endeavor zotarolimus-eluting stent in real-world Japanese patients with coronary artery disease (OPERA): study design and rationale.
Identifieur interne : 000357 ( Main/Curation ); précédent : 000356; suivant : 000358Optimal duration of dual antiplatelet therapy following treatment with the endeavor zotarolimus-eluting stent in real-world Japanese patients with coronary artery disease (OPERA): study design and rationale.
Auteurs : Masato Nakamura [Japon] ; Shinsuke Nanto ; Atsushi Hirayama ; Tadateru Takayama ; Masakatsu Nishikawa ; Kazuo Kimura ; Satoshi Morita ; Tadanori Aizawa ; Ryuta Asano ; Yuji Matsumaru ; Chikuma Hamada ; Takaaki IsshikiSource :
- Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions ; 2014.
Descripteurs français
- Wicri :
- geographic : Japon.
English descriptors
- KwdEn :
- Aged, Coronary Artery Disease (epidemiology), Coronary Artery Disease (therapy), Drug Therapy, Combination, Drug-Eluting Stents, Follow-Up Studies, Humans, Incidence, Japan (epidemiology), Male, Platelet Aggregation Inhibitors (therapeutic use), Practice Guidelines as Topic, Prospective Studies, Prosthesis Design, Sirolimus (analogs & derivatives), Sirolimus (pharmacology), Treatment Outcome.
- MESH :
- chemical , analogs & derivatives : Sirolimus.
- chemical , pharmacology : Sirolimus.
- chemical , therapeutic use : Platelet Aggregation Inhibitors.
- geographic , epidemiology : Japan.
- epidemiology : Coronary Artery Disease.
- therapy : Coronary Artery Disease.
- Aged, Drug Therapy, Combination, Drug-Eluting Stents, Follow-Up Studies, Humans, Incidence, Male, Practice Guidelines as Topic, Prospective Studies, Prosthesis Design, Treatment Outcome.
Abstract
In patients with coronary artery disease (CAD), there is an increasing therapeutic need among interventional cardiologists to conduct dual antiplatelet therapy (DAPT) whose duration is shorter than current guideline-recommended 6-12 months after the implantation of drug-eluting stents. However, no clinical grounds sufficient to rationalize the need are available.
DOI: 10.1002/ccd.25282
PubMed: 24382824
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000183
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000183
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000151
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000B61
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000B61
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000B61
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :000346
Links to Exploration step
pubmed:24382824Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Optimal duration of dual antiplatelet therapy following treatment with the endeavor zotarolimus-eluting stent in real-world Japanese patients with coronary artery disease (OPERA): study design and rationale.</title>
<author><name sortKey="Nakamura, Masato" sort="Nakamura, Masato" uniqKey="Nakamura M" first="Masato" last="Nakamura">Masato Nakamura</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nanto, Shinsuke" sort="Nanto, Shinsuke" uniqKey="Nanto S" first="Shinsuke" last="Nanto">Shinsuke Nanto</name>
</author>
<author><name sortKey="Hirayama, Atsushi" sort="Hirayama, Atsushi" uniqKey="Hirayama A" first="Atsushi" last="Hirayama">Atsushi Hirayama</name>
</author>
<author><name sortKey="Takayama, Tadateru" sort="Takayama, Tadateru" uniqKey="Takayama T" first="Tadateru" last="Takayama">Tadateru Takayama</name>
</author>
<author><name sortKey="Nishikawa, Masakatsu" sort="Nishikawa, Masakatsu" uniqKey="Nishikawa M" first="Masakatsu" last="Nishikawa">Masakatsu Nishikawa</name>
</author>
<author><name sortKey="Kimura, Kazuo" sort="Kimura, Kazuo" uniqKey="Kimura K" first="Kazuo" last="Kimura">Kazuo Kimura</name>
</author>
<author><name sortKey="Morita, Satoshi" sort="Morita, Satoshi" uniqKey="Morita S" first="Satoshi" last="Morita">Satoshi Morita</name>
</author>
<author><name sortKey="Aizawa, Tadanori" sort="Aizawa, Tadanori" uniqKey="Aizawa T" first="Tadanori" last="Aizawa">Tadanori Aizawa</name>
</author>
<author><name sortKey="Asano, Ryuta" sort="Asano, Ryuta" uniqKey="Asano R" first="Ryuta" last="Asano">Ryuta Asano</name>
</author>
<author><name sortKey="Matsumaru, Yuji" sort="Matsumaru, Yuji" uniqKey="Matsumaru Y" first="Yuji" last="Matsumaru">Yuji Matsumaru</name>
</author>
<author><name sortKey="Hamada, Chikuma" sort="Hamada, Chikuma" uniqKey="Hamada C" first="Chikuma" last="Hamada">Chikuma Hamada</name>
</author>
<author><name sortKey="Isshiki, Takaaki" sort="Isshiki, Takaaki" uniqKey="Isshiki T" first="Takaaki" last="Isshiki">Takaaki Isshiki</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="RBID">pubmed:24382824</idno>
<idno type="pmid">24382824</idno>
<idno type="doi">10.1002/ccd.25282</idno>
<idno type="wicri:Area/PubMed/Corpus">000183</idno>
<idno type="wicri:Area/PubMed/Curation">000183</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000151</idno>
<idno type="wicri:Area/Ncbi/Merge">000B61</idno>
<idno type="wicri:Area/Ncbi/Curation">000B61</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000B61</idno>
<idno type="wicri:Area/Main/Merge">000346</idno>
<idno type="wicri:Area/Main/Curation">000357</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Optimal duration of dual antiplatelet therapy following treatment with the endeavor zotarolimus-eluting stent in real-world Japanese patients with coronary artery disease (OPERA): study design and rationale.</title>
<author><name sortKey="Nakamura, Masato" sort="Nakamura, Masato" uniqKey="Nakamura M" first="Masato" last="Nakamura">Masato Nakamura</name>
<affiliation wicri:level="3"><nlm:affiliation>Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Division of Cardiovascular Medicine, Toho University Ohashi Medical Center, Tokyo</wicri:regionArea>
<placeName><settlement type="city">Tokyo</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Nanto, Shinsuke" sort="Nanto, Shinsuke" uniqKey="Nanto S" first="Shinsuke" last="Nanto">Shinsuke Nanto</name>
</author>
<author><name sortKey="Hirayama, Atsushi" sort="Hirayama, Atsushi" uniqKey="Hirayama A" first="Atsushi" last="Hirayama">Atsushi Hirayama</name>
</author>
<author><name sortKey="Takayama, Tadateru" sort="Takayama, Tadateru" uniqKey="Takayama T" first="Tadateru" last="Takayama">Tadateru Takayama</name>
</author>
<author><name sortKey="Nishikawa, Masakatsu" sort="Nishikawa, Masakatsu" uniqKey="Nishikawa M" first="Masakatsu" last="Nishikawa">Masakatsu Nishikawa</name>
</author>
<author><name sortKey="Kimura, Kazuo" sort="Kimura, Kazuo" uniqKey="Kimura K" first="Kazuo" last="Kimura">Kazuo Kimura</name>
</author>
<author><name sortKey="Morita, Satoshi" sort="Morita, Satoshi" uniqKey="Morita S" first="Satoshi" last="Morita">Satoshi Morita</name>
</author>
<author><name sortKey="Aizawa, Tadanori" sort="Aizawa, Tadanori" uniqKey="Aizawa T" first="Tadanori" last="Aizawa">Tadanori Aizawa</name>
</author>
<author><name sortKey="Asano, Ryuta" sort="Asano, Ryuta" uniqKey="Asano R" first="Ryuta" last="Asano">Ryuta Asano</name>
</author>
<author><name sortKey="Matsumaru, Yuji" sort="Matsumaru, Yuji" uniqKey="Matsumaru Y" first="Yuji" last="Matsumaru">Yuji Matsumaru</name>
</author>
<author><name sortKey="Hamada, Chikuma" sort="Hamada, Chikuma" uniqKey="Hamada C" first="Chikuma" last="Hamada">Chikuma Hamada</name>
</author>
<author><name sortKey="Isshiki, Takaaki" sort="Isshiki, Takaaki" uniqKey="Isshiki T" first="Takaaki" last="Isshiki">Takaaki Isshiki</name>
</author>
</analytic>
<series><title level="j">Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions</title>
<idno type="e-ISSN">1522-726X</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Coronary Artery Disease (epidemiology)</term>
<term>Coronary Artery Disease (therapy)</term>
<term>Drug Therapy, Combination</term>
<term>Drug-Eluting Stents</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Incidence</term>
<term>Japan (epidemiology)</term>
<term>Male</term>
<term>Platelet Aggregation Inhibitors (therapeutic use)</term>
<term>Practice Guidelines as Topic</term>
<term>Prospective Studies</term>
<term>Prosthesis Design</term>
<term>Sirolimus (analogs & derivatives)</term>
<term>Sirolimus (pharmacology)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Sirolimus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Platelet Aggregation Inhibitors</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Japan</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronary Artery Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronary Artery Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Drug Therapy, Combination</term>
<term>Drug-Eluting Stents</term>
<term>Follow-Up Studies</term>
<term>Humans</term>
<term>Incidence</term>
<term>Male</term>
<term>Practice Guidelines as Topic</term>
<term>Prospective Studies</term>
<term>Prosthesis Design</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Japon</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">In patients with coronary artery disease (CAD), there is an increasing therapeutic need among interventional cardiologists to conduct dual antiplatelet therapy (DAPT) whose duration is shorter than current guideline-recommended 6-12 months after the implantation of drug-eluting stents. However, no clinical grounds sufficient to rationalize the need are available.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000357 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000357 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Musique |area= OperaV1 |flux= Main |étape= Curation |type= RBID |clé= pubmed:24382824 |texte= Optimal duration of dual antiplatelet therapy following treatment with the endeavor zotarolimus-eluting stent in real-world Japanese patients with coronary artery disease (OPERA): study design and rationale. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:24382824" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \ | NlmPubMed2Wicri -a OperaV1
This area was generated with Dilib version V0.6.21. |